Colon Adenocarcinoma Cell HT-29 Transfection Kit
| Kit size Volume | Quantity | ||
|---|---|---|---|
| 0.5 ml(Cat-177150) | Inquiry | Add to cart | |
| 1.5 ml(Cat-177251) | Inquiry | Add to cart | |
| 8.0 ml(Cat-177353) | Inquiry | Add to cart | |
| 1.5 ml CRISPR(Cat-215752) | Inquiry | Add to cart |
Description
Product Information
Modes of administration
Reagent exhibits at least 70% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Description
HT29 cells were first derived in 1964 from a 44-year-old woman with colon adenocarcinoma. They are a type of human intestinal epithelial cell that produce two substances, Immunoglobulin A and carcinoembryonic antigen. The HT29 cell line is known as heterotransplantable, meaning it can form well-differentiated tumors. The cells have several structures, including microvilli, microfilaments, mitochondria, and smooth and rough endoplasmic reticulum. They also have some lysosomes and express urokinase receptors but not plasminogen activator activity. HT29 cells are negative for CD4 but express galactose ceramide. These cells are frequently used in studies on tumorigenicity and epithelial differentiation. They are also used as a host for research on gastric cancer and infections related to the stomach. CD BioSciences provides nanoparticle-based transfection reagent kits that can be used to deliver substances to HT29 cells without causing significant cell damage.
